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Abstract
Background: Kidney allograft survival continuously improved with introduction of novel immunosuppressants.
However, also immunologically challenging transplants (blood group incompatibility and sensitized recipients)
increase. Between 2006 and 2008, a new tailored immunosuppression scheme for kidney transplantation was
implemented at the University Hospital in Zurich, together with an ABO-incompatible transplant program and
systematic pre- and posttransplant anti-human leukocyte antigen (HLA) antibody screening by Luminex technology.
This study retrospectively evaluated the results of this tailored immunosuppression approach with a particular focus
on immunologically higher risk transplants.
Methods: A total of 204 consecutive kidney transplantations were analyzed, of whom 14 were ABO-incompatible
and 35 recipients were donor-specific anti-HLA antibodies (DSA) positive, but complement-dependent cytotoxicity
crossmatch (CDC-XM) negative. We analyzed patient and graft survival, acute rejection rates and infectious
complications in ABO-compatible versus -incompatible and in DSA positive versus negative patients and compared
those with a historical control group.
Results: Overall patient, death-censored allograft survival and non-death-censored allograft survival at 4 years were
92, 91 and 87%, respectively. We found that (1) there were no differences between ABO-compatible and
-incompatible and between DSA positive and DSA negative patients concerning acute rejection rate and graft
survival; (2) compared with the historical control group there was a significant decrease of acute rejection rates in
sensitized patients who received an induction with thymoglobulin; (3) there was no increased rate of infection
among the patients who received induction with thymoglobulin compared to no induction therapy.
Conclusions: We observed excellent overall mid-term patient and graft survival rates with our tailored
immunosuppression approach. Induction with thymoglobulin was efficient and safe in keeping rejection rates low
in DSA positive patients with a negative CDC-XM.
Keywords: Kidney transplantation, Induction therapy, Thymoglobulin, Donor-specific antibodies, ABO-
incompatibility, Rejection
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Background
Allograft survival after kidney transplantation has sub-
stantially improved with modern immunosuppressive
drugs - particularly in the first year post-transplant -,
but still 5–10% of patients suffer from acute rejection,
which overall leads to a reduced graft survival [1–3].
General risk factors for acute rejection and a shortened
graft survival are prolonged cold ischemia time, body
mass index (BMI) > 25 kg/m2, AB0 incompatibility,
number of human leukocyte antigen (HLA) mismatches
and retransplantation [4]. Furthermore, several studies
demonstrated that the presence of donor-specific anti-
HLA antibodies (DSA) increased the risk of antibody-
mediated rejection (AMR) and was deleterious for allo-
graft survival [5–9]. To avoid immunologically incom-
patible transplantation (AB0 incompatibility, DSA
positive patients) paired kidney donation was introduced
in many countries including Switzerland, a procedure
allowing conversion of incompatible to compatible pairs
[10]. If this is not possible risk-adapted immunosuppres-
sion and/or desensitization represent alternative options
[11]. Depending on the immunological risk, this can be
performed using anti-thymocyte globulin such as thymo-
globulin or rituximab induction and/or intravenous im-
munoglobulin with or without plasmapheresis/
immunoadsorption [12]. Previous studies showed that
induction with thymoglobulin leads to a reduction of
acute rejections in DSA positive, complement-dependent
cytotoxicity crossmatch (CDC-XM) negative patients
[13–15].
Based on these observations a new tailored immuno-
suppression scheme was implemented at the University
Hospital Zurich between 2006 to 2008 (Table 1). For
DSA positive patients a risk-adapted immunosuppres-
sion protocol including thymoglobulin induction was
introduced, alongside with the universal pre- and post-
transplant monitoring of anti-HLA antibodies using the
Luminex technology; furthermore, a program for ABO-
incompatible transplantation using rituximab induction
was started.
In this retrospective study we investigated in a single
center real life setting how efficient this new tailored im-
munosuppression strategy was in terms of overall patient
and graft survival after 4 years, in avoiding acute
rejections in patients with preformed DSA compared to
non-sensitized patients and in ABO-incompatible trans-
plantations, and we compared the results in sensitized
patients with DSA to the period prior to the introduc-
tion of this new immunosuppression scheme.
Methods
Patients
Between October 2008 and March 2011 a total of 219
kidney transplantations were performed at the University
Hospital of Zurich. These patients were retrospectively
included in our study. Pediatric patients were excluded,
because they had their follow-up at the Zurich Univer-
sity Children’s Hospital (n = 10). Also excluded were
patients, who had a combination of kidney and liver
transplantation (n = 5), because of the postulated immu-
nomodulatory effects of the liver graft [16]. Therefore,
204 patients (including combined kidney/pancreas and
kidney/islet transplants) could be evaluated. Observation
time was between 0 and 61.4 months (Median 41.2, 25%
quartile: 33.6, 75% quartile: 48.6). This retrospective ana-
lysis was approved by the local ethics committee of the
Canton of Zurich (KEK-10: 2012–0247).
Screening for viral infections
BK polyomavirus screening by urinary polymerase chain
reaction (PCR) was performed at 0, 3, 6, 9, 12, 18 and
24months after transplantation. A cytomegalovirus
(CMV) preemptive therapy approach was chosen at our
center, with a clearly defined schedule for CMV PCR
monitoring depending on the serostatus of donor and
recipients [17]. No systematic screening for Epstein-Barr
virus was performed.
Table 1 Tailored immunosuppressive regimens in the Zurich renal transplant program before 2006 and from 2008 to 2011
Regimen Patient group Transplantation until 2006 Transplantation from 2008
1 first transplantation without anti-HLA
immunization
cyclosporine, MMF, prednisone cyclosporine, MMF, prednisone
2a retransplantation and/or anti-HLA
immunization, but without DSA
basiliximab, tacrolimus, MMF, prednisone basiliximab, tacrolimus, MMF, prednisone
2b recipient with DSA and negative CDC cross-
match
basiliximab, tacrolimus, MMF, prednisone thymoglobulin, tacrolimus, MMF,
prednisone
3 donor risk (age above 75, cold ischemia time >
24 h, DCD)
thymoglobulin, tacrolimus delayed (day 5),
MMF, prednisone
thymoglobulin, tacrolimus delayed (day 5),
MMF, prednisone
4 ABO blood group incompatibility (not performed) rituximab + IADS, tacrolimus, MMF,
prednisone
CDC Complement-dependent cytotoxicity, DCD Donor after circulatory death, DSA Donor-specific antibody, IADS Immunoadsorption with Glycosorb column,
MMF Mycophenolate-mofetil
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Immunosuppressive regimen
The revised standard immunosuppressive regimens
starting from summer 2008 are summarized in Table 1.
For patients with DSA the induction therapy with basi-
liximab (standard dose of 2 × 20mg) was replaced by
anti-thymocyte globulin (thymoglobulin). Patients
receiving an organ from a donor with risk factors for de-
layed graft function (higher age, longer cold ischemia
time, donors after circulatory death) also received thy-
moglobulin in association with a delayed start of tacroli-
mus. The total dose of thymoglobulin was 1.5 mg/kg
body weight on 5 consecutive days (i.e. the maximum
dose was 7.5 mg/kg body weight). In case of profound
lymphopenia the dose was reduced, but all patients re-
ceived at least 3 doses. Outside of the regular immuno-
suppression schemes, three patients received de novo
everolimus with sotrastaurin in the context of a clinical
study protocol [18]. These three patients remained
included in the overall analysis of patient and graft sur-
vival. For patients with ABO incompatibility the induc-
tion therapy was performed with rituximab. One single
dose of rituximab (375 mg/m2) was given 4 weeks before
transplantation. The initial steroid dose was identical for
all protocols: solumedrol 500 mg i.v. on day 0, prednis-
one 100 mg p.o. on postoperative day 1 + 2, prednisone
0.5 mg/kg body weight p.o. from day 3 to day 14. A stan-
dardized tapering protocol was followed thereafter. Dos-
ing of immunosuppressive drugs was standardized and
tightly supervised. In combination with mycophenolate-
mofetil (MMF) the target blood levels for cyclosporine
were: 200–250 ng/ml (week 0–5), 180–220 ng/ml (week
6–11), 150–200 ng/ml (week 12 - month 5), 100–160
ng/ml (month 6–11), 80–120 ng/ml (month 12–17), 60–
100 ng/ml (month 18–23) and 50–80 ng/ml thereafter.
The doses for MMF in combination with cyclosporine
were 1500mg bid on day 0, 1500mg bid on day 1–14
(dose reduction to 1000mg bid in case of body weight <
50 kg or profound neutropenia) and 1000 mg bid from
day 15. Also, in combination with MMF the target blood
levels for tacrolimus were: 10–15 μg/l (week 0–5), 8–12
μg/l (week 6–11), 7–10 μg/l (week 12 - month 11), 6–8
μg/l (month 12–23), 4–6 μg/l thereafter. The doses for
MMF in combination with tacrolimus were 1000mg bid
on day 0, 1000mg bid on day 1–14 (dose reduction to
750 mg bid in case of body weight < 50 kg or profound
neutropenia) and 750 mg bid from day 15.
Anti-HLA antibody screening
Patients were screened for anti-HLA antibodies with
Luminex LABScreen Mixed (One Lambda Inc., Canoga
Park, CA, USA). This kit contains a panel of
fluorescence-labeled microbeads coated with purified
HLA antigens to identify anti-HLA class I or II IgG [19].
Test interpretation was performed using HLA Visual
software (OneLambda Inc.) on the LABScan 100 flow-
cytometer (Luminex Inc., Austin, TX, USA).
Single-antigen bead assay (SAB)
To identify the specificity of anti-HLA IgG antibodies,
we performed the high-definition LABScreen Single
Antigen (OneLambda) class I assay in LABScreen Mixed
class I positive individuals and a class II assay in LABSc-
reen Mixed class II positive individuals [20]. For result
interpretation, Labscan 100 software (One Lambda) was
used. The cut-off for a positive result was set at 500
mean fluorescence intensity (MFI) according to the
manufacturer’s instruction.
A patient was classified as DSA positive when at least
one DSA with MFI > 500 was detected. DSA were
accepted up to MFI 10`000, when CDC-XM was nega-
tive. No flowcytometry-XM was performed.
Outcome parameters
This retrospective analysis focused on the efficacy of the
new tailored immunosuppressive scheme in a single cen-
ter analysis in terms of overall patient and allograft sur-
vival, in prevention of acute rejection and allograft loss
in DSA positive patients in comparison to DSA negative
patients and in ABO-incompatible transplantations. The
results in DSA positive patients were compared to the
period previous to the introduction of thymoglobulin
induction. All clinically suspected rejections were con-
firmed by a renal allograft biopsy. Biopsy specimens
were evaluated by light microscopy and immunofluores-
cence including C4d staining. The histologic classifica-
tion followed the Banff 2007 criteria [21].
Secondary outcome parameters included graft function
and the incidence of infectious complications as the
main safety parameter. Graft function is indicated as
chronic kidney disease (CKD) stage since calculation of
estimated glomerular filtration rate (GFR) was changed
from MDRD to CKD-EPI formula during the study
period and therefore not comparable among all patients.
Statistical methods
Data were registered in MS Excel and analyzed with
SPSS version 22. Mean and standard deviations were cal-
culated for continuous variables and relative frequencies
for discrete variables. Differences in medians of a con-
tinuous variable between two groups were checked with
the non-parametric Mann-Whitney test. Associations
between two discrete variables were evaluated with the
Chi2-test.
Survival analysis with Kaplan-Meier survival curves
estimation was considered for patient survival, graft sur-
vival and rejection-free survival. Observations, where
death of a patient occurred, were considered as uncen-
sored, whereas surviving patients were censored at the
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last day of follow-up. A similar type of censoring defin-
ition was applied to graft survival and rejection-free sur-
vival. In addition, the log-rank and Breslow-Gehan tests
were performed for discrete predictors. The impact of a
continuous predictor on survival was estimated by the
Cox-regression.
Results of the statistical analysis with P-value < 0.05
were referred as statistically significant.
Results
Patient population
Baseline characteristics of patients are reported in
Table 2.
The most frequent primary diseases leading to renal
failure were glomerulonephritis or vasculitis (29.9%), dia-
betic nephropathy (17.6%) and cystic kidney disease
(15.2%). Interestingly, in the group of DSA positive pa-
tients glomerulonephritis was almost twice as frequent
compared to the DSA negative group.
With regard to induction therapy, the following agents
were used: 47 patients received thymoglobulin (23.0%),
46 received basiliximab (22.5%), 7 received rituximab
(3.4%) and 4 patients received a combination (2.0%,
shown in Table 2). Overall, 14 patients underwent ABO
blood group incompatible transplantation.
When looking closer at DSA, 35 (17.2%) among the
204 kidney recipients were DSA positive: 10 of them
were only positive for class I, 18 were only positive for
class II and 7 were positive for class I and II. Detailed in-
formation on specificity and titers of anti-HLA anti-
bodies are given in Supplementary Table 1. As expected,
the percentage of patients receiving a second or third
transplant was significantly higher (48.6%) in the DSA
positive group compared to the DSA negative group
(8.9%). The majority of DSA positive patients received
induction with thymoglobulin (74.3%), 7 received basilix-
imab (20%) and 4 rituximab (11.4%), in whom 3 also had
a blood group incompatibility. Details on blood group
incompatibilities and pre-transplant isoagglutinine titers
are given in Supplementary Table 2.
Patient survival
The overall survival of the 204 kidney transplants recipi-
ents was 95% at 1 year and 92% at 4 years (Fig. 1a). This
result was similar to the survival rates in the Collabora-
tive Transplant Study (CTS; transplant period 2000–
2017; graph E-11012-0219). Among patients with blood
group incompatibility all survived during the 4-year
follow-up. Thereby, it needs to be considered, that all
ABO incompatible transplantations were living donor
transplants, which in general have a better outcome
(Fig. 2a, p = 0.294). Also, between patients without and
with DSA no difference in patient survival was observed,
despite heavier immunosuppression in the latter (Fig. 3a,
p = 0.497).
Death-censored graft survival
The overall death-censored graft survival was 94% at 1
year and 91% at 4 years (Fig. 1b). These survival rates fa-
vorably compared to the respective rates in the CTS
(transplant period 2000–2016; 1 year: 92%; 4 years: 83%;
graph E-11011-0818). No difference was found between
ABO incompatible and ABO compatible transplanta-
tions (Fig. 2b, p = 0.746) as well as between DSA positive
and DSA negative recipients (Fig. 3b, p = 0.551). Espe-
cially the latter was a reassuring finding and confirmed
the protective effect of thymoglobulin in sensitized pa-
tients with negative CDC cross-match – as suggested in
the literature. This was further confirmed by an analysis
of death-censored graft survival in the subgroup of
thymoglobulin-treated patients only, which also showed
no difference between DSA positive and DSA negative
patients (data not shown).
Rejection-free survival
The overall rejection-free survival was 67.4% at 1 year,
again with no difference between DSA positive and DSA
negative patients, as was the case also for ABO incom-
patible transplantations. Overall 17 patients (8.4%) expe-
rienced an AMR episode.
We took a closer look at different induction therapies.
Approximately half of the patients received no induction
(all non-sensitized patients receiving their first trans-
plant: immunosuppression regimen 1 in Table 1), basi-
liximab and thymoglobulin were roughly equally
distributed (Fig. 4a). ABO incompatible patients received
rituximab, combinations of different induction agents
were very rarely used. Induction therapy turned out to
be the most important factor in preventing acute rejec-
tion, since patients with any type of induction performed
better than patients without induction (Fig. 4b, p =
0.006). Between the two most frequently used induction
therapies (basiliximab and thymoglobulin), no difference
was found in acute rejection rates (Fig. 4c, p = 0.656).
Allograft function after 1 year
The median of CKD stage overall 1 year after transplant-
ation was 2 (25. percentile = 1, 75. percentile = 3), and no
difference was found between DSA positive and DSA
negative patients (p = 0.226). Concerning proteinuria
after 1 year there was also no difference between the
groups.
Comparison with historical controls at our center
For a comparison of AMR incidence in sensitized recipi-
ents with a period before introduction of thymoglobulin
induction, we used our own historical data, which were
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collected between 2005 and 2008 and published in 2010
[7]. Whereas in the study of Riethmüller et al. DSA posi-
tive patients experienced a significantly higher incidence
of AMR than DSA negative patients (Table 3, p < 0.001),
this difference could not be seen after the introduction
of thymoglobulin induction therapy in the current study
(Table 3, p = 0.332).
The incidence of AMR in this high risk group was
reduced from 35% in the historical controls to 11.4%
in the current study. Similarly, the incidence of T








Recipient age (year), mean (SD) 51 (±13) 51 (±12) 49 (±14) 0.428
Female sex, n (%) 83 (40.7) 63 (37.3) 20 (57.1) 0.024
Primary renal disease, n (%) 0.517
Vascular/hypertensive 18 (8.8) 15 (8.9) 3 (8.6)
Diabetic 36 (17.6) 33 (19.5) 3 (8.6)
Glomerulonephritis/vasculitis 61 (29.9) 45 (26.6) 16 (45.7)
Cystic 31 (15.2) 26 (15.4) 5 (14.3)
Urological 17 (8.3) 14 (8.3) 3 (8.6)
Tubulointerstitiell 9 (4.4) 7 (4.1) 2 (5.7)
HUS/TTP 1 (0.5) 1 (0.6) 0 (0.0)
Others 8 (3.9) 7 (4.1) 1 (2.9)
Indefinite 23 (11.3) 21 (12.4) 2 (5.7)
Dialysis, n (%) 173 (84.8) 141 (83.4) 32 (91.4) 0.175
Number of transplantation, n (%) < 0.001
First 172 (84.3) 154 (91.1) 18 (51.4)
Second 30 (14.7) 15 (8.9) 15 (42.9)
Third 2 (1.0) 0 (0.0) 2 (5.7)
Donor type, n (%) 0.547
Living 69 (33.8) 57 (33.7) 12 (34.3)
Deceased 135 (66.2) 112 (66.3) 23 (65.7)
Type of transplantation, n (%) 0.195
Kidney 180 (88.2) 146 (86.4) 34 (97.1)
Kidney + pancreas 21 (10.3) 20 (11.8) 1 (2.9)
Kidney + pancreatic islets 3 (1.5) 3 (1.8) 0 (0.0)
Blood group incompatibility, n (%) 14 (6.9) 11 (6.5) 3 (8.6) 0.443
HLA mismatches, mean (SD) 4.6 (±1.9) 4.5 (±1.9) 5.2 (±1.8) 0.228
Induction treatment, n (%)
Thymoglobulin 47 (23.0) 22 (13.0) 25 (71.4) < 0.001
Basiliximab 46 (22.5) 41 (24.3) 5 (14.3) 0.143
Rituximab (overall) 11 (5.4) 7 (4.1) 4 (11.4) 0.098
Rituximab alone 7 (3.4)
Rituximab and basiliximab 3 (1.5)
Rituximab and thymoglobulin 1 (0.5)
Maintenance immunosuppression, n (%)
Cyclosporine A 96 (47.1) 94 (55.6) 2 (5.7) < 0.001
Tacrolimus 103 (50.5) 70 (41.4) 33 (94.3) < 0.001
aAbbreviations: DSA Donor-specific antibody, SD Standard deviation, n Number, HUS Hemolytic uremic syndrome, TTP Thrombotic thrombocytopenic purpura, HLA
Human leukocyte antigen
bSensitizing events in the DSA positive group: previous transplantation 51.4%, pregnancy history 11.4%, previous blood transfusion 51.4%
Good-Weber et al. BMC Nephrology          (2020) 21:501 Page 5 of 10
cell-mediated rejection (TMR) was reduced from 40
to 20% (Table 3). Thus, thymoglobulin induction had
a protective effect against early acute rejection (AMR
and TMR) in immunologically high risk patients with
DSA.
Infectious complications
The most common events were bacterial infections and
viral infections with CMV or BK polyomavirus. Overall
33% of patients experienced bacterial infections leading
to hospitalization. Furthermore, 70% suffered from
viremia in the first year: 49.3% with CMV and 28.6%
with BK polyomavirus. As shown in Table 4, we found
that patients who received induction therapy did not ex-
perience more infections than those who had no induc-
tion. Also, the number of hospitalizations due to
infections was comparable with or without induction
therapy except for CMV viremia, which was lower in
basiliximab-treated patients during the first year (Table 4,
p = 0.023).
Fig. 1 Outcome of kidney transplantation overall (n = 204 patients). Kaplan-Meier survival curves are shown for (a) patient survival and (b) death-
censored graft survival
Fig. 2 Outcome of kidney transplantation in ABO compatible (n = 189) versus ABO incompatible (n = 14) patients. Kaplan-Meier survival curves
are shown for (a) patient survival and (b) death-censored graft survival
Good-Weber et al. BMC Nephrology          (2020) 21:501 Page 6 of 10
Fig. 3 Outcome of kidney transplantation in DSA negative (DSA-, n = 168) and DSA positive (DSA+, n = 35) patients. Kaplan-Meier survival curves
are shown for (a) patients survival and (b) death-censored graft survival
Fig. 4 Induction therapies and rejection-free survival. a Distribution of the different induction therapies in the whole study group (n = 204
patients). b Comparison of acute rejection-free survival between patients with and without any type of induction therapy. c Comparison of acute
rejection-free survival between the two most important induction therapies thymoglobulin and basiliximab (p = 0.656). Acute rejection rates after
12 months were 22.9% for thymoglobulin, 28.4% for basiliximab and 40.6% for the no induction group
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Discussion
Despite modern immunosuppression 5–10% of renal
transplant patients still experience acute rejection lead-
ing to an overall reduced graft survival [1–3]. There are
currently no randomized controlled trials defining the
optimal immunosuppressive strategy in immunologically
high-risk recipients. This study retrospectively tested the
efficacy of a tailored immunosuppression approach in
kidney transplant recipients with risk-stratified treat-
ment protocols for five different patient categories in
our center. The main findings are the following: (1) we ob-
served excellent patient and allograft survival rates at 1
and 4 years post-transplant; (2) we found no differences
between sensitized patients (ABO compatible versus in-
compatible, DSA positive versus DSA negative) regarding
acute rejection rates and graft survival; (3) compared with
a historical control group at our center there was a signifi-
cant reduction of antibody- and T cell- mediated rejection
in sensitized thymoglobulin-treated patients; (4) there was
no increased rate of infections leading to hospitalization
among patients receiving thymoglobulin, but an increased
incidence of CMV viremia, as confirmed by a recent
Cochrane database review [22, 23].
The optimal treatment strategy for patients sensitized
to the HLA antigens of their donor is unclear. In theory,
the best option is avoiding transplantation across DSA, a
strategy which can be achieved by paired kidney
donation in living donor transplantation [10] and by
acceptable mismatch programs in deceased donor trans-
plantation [24]. But even after implementing such
programs a patient population remains, where no alter-
native option to crossing DSA exists. Whereas most
centers are reluctant to transplant across a positive
CDC-XM, they may accept an organ with a negative
CDC-XM, but presence of DSA up to a certain MFI
value. However, it is unclear what the optimal immuno-
suppressive strategy in this situation is. Some centers
have suggested induction therapy with rituximab and/or
intravenous immunoglobulins [25–27], but other reports
showed a limited efficacy of this strategy in terms of pre-
vention of AMR and graft survival [28, 29]. Alternatively,
some centers have reported a reduction in acute rejec-
tion rate by the use of thymoglobulin induction therapy
in this patient population [13, 14, 30–32]. For example,
the Basle group showed a significant reduction of clinical
and subclinical AMR and TMR in their patient groups
which however was monitored by protocol biopsies [14].
In contrast to our study, they used thymoglobulin com-
bined with high dose intravenous immunoglobulins,
whereas in our study only thymoglobulin was used. The
effect on the incidence of clinical acute rejection was
comparable suggesting that adding intravenous immu-
noglobulins might not be necessary. However, we did
not perform protocol biopsies and therefore cannot
argue concerning subclinical rejection episodes.
ABO blood group-incompatible kidney transplantation
has been implemented in many centers around the
world including also 5 of the 6 kidney transplant centers
in Switzerland. We previously reported the Swiss experi-
ence, which showed excellent results in patient and
death-censored graft survival [10], although a higher rate
of mild cellular rejection was observed with late steroid
withdrawal [17]. Here, we show our results in Zurich
with absolute identical outcomes in patient and allograft
Table 3 Incidence of acute rejection in current population and historical controls










AMR, n (%) 1 (0.7) 7 (35.0) < 0.001 13 (7.7) 4 (11.4) 0.332
TMR, n (%) 31 (22.9) 8 (40.0) 0.090 58 (34.5) 7 (20.0) 0.067
HLA Hyuman leukocyte antigens, DSA Donor-specific antibody, AMR Antibody-mediated rejection, TMR T-cell-mediated rejection
Table 4 Infectious complications








Bacterial infection, n (%) 35 (36.8) 13 (28.9) 16 (36.4) 0.633
Viremia, n (%)
Cytomegalovirus 59 (61.5) 17 (37.0) 23 (51.1) 0.023
BK Polyomavirus 25 (26.0) 15 (32.6) 17 (37.8) 0.346
Hospitalisation due to
Infection, n (%) 37 (38.9) 14 (31.1) 18 (40.9) 0.581
aCombinations of different induction therapies (n = 4) and induction with rituximab (n = 7) were not included in the statistical evaluation because of the
small number
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survival with ABO-compatible transplants in an unse-
lected patient population.
The strengths of our study are (1) a highly standard-
ized, single center patient follow-up of nearly 100% up
to 1 year; (2) the use of a defined and uniform risk-
adapted immunosuppressive concept in our center,
tightly overviewed by one of us (T.F.); (3) the availability
of results of pretransplant anti-HLA antibodies based on
Luminex SAB analysis in 100% of patients. However, our
study also has two main limitations: first, the overall rate
of acute rejections was relatively high. The main reason
for this was that in non-sensitized patients receiving
their first transplant no induction therapy was given.
This concept has subsequently been changed in our cen-
ter after 2011. The second limitation is that the study
was not randomized. However, the nearly 100% follow-
up of our patient population, the detailed subgroup ana-
lyses, the direct comparison to historical controls at the
same center in the immediately preceding time period,
provide clinical data representing real life transplant
medicine without any particular patient selection apart
from the exclusion of pediatric patients. The third
limitation consists in the fact that some subgroups were
limited in size, which is only partially compensated by a
very homogeneous and highly structured follow-up of
these patients in a tightly supervised single-center
setting.
Conclusions
In conclusion, a tailored immunosuppression using five
different immunosuppression regimens for specific
patient categories was efficient and increased the graft-
and rejection-free- survival in sensitized patients.
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